Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus trastuzumab/pertuzumab/docetaxel vs carboplatin plus trastuzumab/pertuzumab/docetaxel as neoadjuvant therapy for HER2-positive breast cancer
ChiCTR2500113994Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of QL1706 in breast cancer (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Total pathological complete response rate (tPCR: ypT0/Tis ypN0). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500113994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113994.